In the past 15 years, the proteasome has been validated as an anti-cancer drug target and
20S proteasome inhibitors (such as bortezomib and carfilzomib) have been approved by the …

Acamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator
approved by the Food and Drug Administration (FDA) as a pharmacological treatment for …

Background: Sub-anesthetic ketamine administration may be helpful for substance use
disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions …

Using a well-established model of ethanol dependence and relapse, this study examined
adaptations in glutamatergic transmission in the nucleus accumbens (NAc) and their role in …

Approximately one-half of patients with alcohol use disorder who abruptly stop or reduce
their alcohol use will develop signs or symptoms of alcohol withdrawal syndrome. The …

Alcohol use disorder (AUD) is highly prevalent and among the leading causes of morbidity
and mortality in the United States. Pharmacotherapies for AUD are limited, thus making …

Background The medial prefrontal cortex (mPFC) inhibits impulsive and compulsive
behaviors that characterize drug abuse and dependence. Acamprosate is the leading …

Acinetobacter baumannii (A. baumannii) is a common opportunistic nosocomial pathogen,
which is able to produce biofilms on the surface of indwelling medical devices, and …

Alcohol use disorder (AUD) represents a serious public health issue, and discovery of new
therapies is a pressing necessity. Alcohol exposure has been widely demonstrated to …

Objective To provide primary care physicians with evidence-based information and advice
on the management of at-risk drinking and alcohol use disorder (AUD). Sources of …